T1	Participants 142 238	polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis.
T2	Participants 274 293	sixty-two patients.
T3	Participants 348 414	severe polyarteritis nodosa (PAN) and Churg-Strauss syndrome (CSS)
T4	Participants 555 821	62 patients were randomly assigned to receive either prednisone plus cyclophosphamide (intravenous bolus) (group A; n = 28) or prednisone plus cyclophosphamide (intravenous bolus) plus plasma exchanges (group B; n = 34) as first-line treatment for severe PAN or CSS.
